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2Motivations
 To investigate network configurations that are most conducive to knowledge
creation
– Multiple types of network configurations: e.g. structure and composition
– Multiple types of knowledge outcomes: e.g. scientific and technological
... mixed findings and unsolved conceptual puzzles
 Networks in the context of biomedical research
– Translational Research has become a high policy priority with the aim to improve
healthcare by strengthening research collaborations between basic and clinical
scientists
... but there is a lack of consensus about whether and to what extent current
initiatives to support Translational Res. have been really effective
 Improve our understanding of how (biomedical) research networks work
MOTIVATION OF THIS RESEARCH
3BACKGROUND
Social network literature
 “People who do better are somehow better connected” (Burt, 2000)
– Holding a particular position in a network can be an asset in its own right, as it
influences the amount of resources and opportunities available
 However, it is not clear what better connected means:
– being better connected does not necessarily mean being more connected
– There are different mechanisms to reach advantageous positions in a network
 Two critical aspects of network configurations
‒ Structure: Dense (Coleman, 1988) vs. Sparse (Burt, 1992; Granovetter, 1973) networks
‒ Composition: Homogeneous vs. Heterogeneous actors (Fleming et al., 2007; Reagans
& McEvily, 2003)
4BACKGROUND
Network structure: Dense vs. Sparse networks
Dense Networks Sparse Networks
Networks where everyone is highly connected to 
each other
 Fast access to information
 Reliable communication, people trust each other      
(cheating and non-reciprocity are socially sanctioned)
Few connections between alters / More 
opportunities to act as a bridge between actors -
brokers - and control information flows 
 High access to non-redundant information 
 Unique conditions to identify new opportunities
Sparse networks should increase the exposure to different approaches and sources 
of information, but they may involve lack of mutual trust and slower circulation of 
information among partners compared to dense networks. 
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Network composition: homogeneous vs. heterogeneous actors
Network composition refers to the diversity of actors involved in a personal network
CENTRAL ACTORDIVERSITY of ACTORS
(where colours represent different attributes of actors)
Heterogeneity in network 
composition should favour access to 
non-redundant information
… but it may require greater 
coordination and cognitive efforts 
compared to more homogeneous
networks
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Personal network structure / composition and medical innovation
 Actors who have access to diverse sources of information and knowledge as a result of:
– holding brokerage positions - connecting actors who otherwise would be disconnected
– building ties to heterogeneous actors
… are expected to have an advantage for knowledge creation (Burt,1992; Fleming et.al, 2007;
Reagans & McKevily, 2003)
 However, actors may face increasing difficulties to benefit from sparse or heterogeneous
networks due to:
– potential lack of mutual trust and weakened expectations on the credibility of partners
– potential lack of shared cognitive frames and risks of misperceptions
 … We expect sparse networks / heterogeneity in network composition to facilitate medical
innovation up to a point, beyond which enlarging the range of disconnected / heterogeneous
relationships can be either ineffective or detrimental for innovation (Baer, 2010;Fang et al., 2010;
McFadyen & Cannella, 2004; ter Wal et al., 2013).
Hypothesis 1: Scientists with personal networks characterized by a high degree of brokerage will
be more likely to engage in medical innovation. Engagement in innovation will be maximized at
intermediate levels of brokerage (inverted U-shape).
Hypothesis 2: Scientists with personal networks characterized by high degree of actor
heterogeneity will be more likely to engage in medical innovation. Engagement in innovation
will be maximized at intermediate levels of actor diversity (inverted U-shape).
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Social network research and characteristics of actors in the network
 Network research has often treated actors as undifferentiated: e.g. cognitive hollow
(Phelps et al., 2012)
 However:
– Differences in Individual behaviour cannot be solely explained by structure-level
characteristics. We need to bring the individual back when conducting social
network research (Ibarra, Kilduff & Tsai, 2005)
 Individual differences might refer to:
– Cognitive frames and skills (Rotolo & Messeni-Petruzzelli, 2012)
– Personality traits (Fini et al., 2012)
– Motivations and attitudes (Mehra et al 2001)
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Social network research and characteristics of actors in the network
We consider two types of characteristics regarding central actors:
 Cognitive skills
Engagement in medical innovation requires that scientists should be familiar with a combination
of basic and clinical skills (Hobin et al, 2012).
Hypothesis 3: Breadth of cognitive skills will have a positive relationship with the scientists’ 
degree of engagement in medical innovation.
Perceived impact on beneficiaries is the degree to which individuals are aware that their own 
actions have the potential to improve the welfare of others (Grant, 2007, 2008). This awareness is 
claimed to exert an influence on individuals’ disposition to channel this perception into outcomes.
Hypothesis 4: The perceived impact of research on patients and medical practitioners will 
have a positive relationship with the scientists’ degree of engagement in medical innovation.
 Perceived impact on beneficiaries
9RESEARCH CONTEXT AND METHODS
Spanish Biomedical Research Networking Centers (CIBERs) are formal
network platforms created by the Spanish Ministry of Health in 2007.
Aims of the CIBER networks:
 Foster research collaboration by bringing together research groups from
universities, hospitals, research centres and firms working on similar pathologies.
 Organize biomedical research around nine broad range of pathologies of critical
interest for the Spanish National Health System:
• Bioengineering, Biomaterials and Nanomedicine
• Diabetes and Metabolic Associated Diseases
• Epidemiology and Public Health
• Hepatic diseases
• Mental Health
• Neurodegenerative diseases
• Obesity and Nutrition
• Rare Diseases
• Respiratory Diseases
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RESEARCH CONTEXT AND METHODS (II)
SURVEY DATA
 Sample frame for the study:
– All biomedical scientists and technicians belonging to research groups in each
of the nine CIBER networks (4,758 individuals)
 Implementation of a survey
– We designed a questionnaire to collect information on the following aspects
• collaborative network (external to the scientist’ research team)
• individual attributes of scientists
• degree of engagement in multiple activities related to medical innovation
– Using email addresses, scientists were invited to participate an on-line survey
(between April and June, 2013)
– Overall response rate = 27.5 % (1,309 valid responses)
• Non-response bias tests by type of institution, group size, status and CIBERs
SECONDARY SOURCES
 Records of patent applications from PIs (period 1990-2010)
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VARIABLES
 Dependent variable: Degree of engagement in (multiple types of) medical
innovation
We asked respondents to report “how many times” they have participated in any of the 
following activities during the year 2012.
Included items in the questionnaire
Patent applications for new drugs
Licenses from patents 
Participation in spin-off
Clinical trials phases I, II or III for new drugs development
Clinical trials phase IV for new drugs development
Clinical trials phase IV for new diagnostic techniques
Clinical guidelines for healthcare professionals
Clinical guidelines for patients
Patent applications for new diagnostic techniques
Clinical trials phases I, II or III for new diagnostic techniques
Clinical guidelines for the general population (prevention)
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VARIABLES
 Dependent variable: Degree of engagement in (multiple types of) medical
innovation
We asked respondents to report “how many times” they have participated in any of the 
following activities during the year 2012.
Included items in the questionnaire Categories
Patent applications for new drugs
Invention and 
Commercialization
Licenses from patents 
Participation in spin-off
Clinical trials phases I, II or III for new drugs development
New Drug DevelopmentClinical trials phase IV for new drugs development
Clinical trials phase IV for new diagnostic techniques
Clinical guidelines for healthcare professionals
Clinical Guidelines
Clinical guidelines for patients
Patent applications for new diagnostic techniques
Diagnostics and PreventionClinical trials phases I, II or III for new diagnostic techniques
Clinical guidelines for the general population (prevention)
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VARIABLES
 Distribution of respondents across the categories of the DV (%)
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 DV: Degree of engagement in Med. Innov.- ranges between 0 and 3 according 
to the participation in the four types of medical innovation:
“0”: No participation in any of the four types of innovation
“1”: Participated at least once in one of the four types of innovation
“2”: Participated  at least once in two of the four types of innovation
“3”: Participated at least once in three or four innovation types.
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MEASURE of Network Structure
Personal (ego) network brokerage as: 1 -
Scientist A
6 alters reported
Brokerage score = 0,933
Scientist B
6 alters reported
Brokerage score = 0,267
 Independent variable I: Ego-network brokerage
Number of alter-alter ties
total number of possible
alter-alter ties
Min = 0 (lowest brokerage)   
Max = 1 (highest brokerage)
High Brokerage
(sparse network)
Low Brokerage
(dense network)
We measured network brokerage as the rate of actual connections / potential connections 
between each respondents’ contacts from outside her research group.
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MEASURE of Network Structure
 Independent variable I: Ego-network brokerage
Frequency of scientists according to their brokerage score
Frequencies are largest at the extremes of the distribution: scores of 0 and 1
Ego-Net. Brokerage:
Mean: 0.63
Median: 0.70
Mode: 1.00
Min:  0.00
Max: 1.00
(figures for actors who 
report 2 or more 
external alters)
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MEASURE of Network Composition
 Independent variable II: Network_Range
This measure is built from another question in the survey, asking for the following 
information about the contacts cited by the respondent:
“Indicate the sector or professional field of the persons you have cited as being a particularly 
important source of information or advice for your research activities” (drop-down menu)
Basic 
Scientist 
(NHS, Uni)
Clinical 
Scientist 
(NHS, Uni)
Medical Doctor 
(not involved 
in research)
Patient or 
Patient 
Associations
Industry / 
Private 
Sector
Public 
Administ
Others 
(specify)
Alter 1 □ □ □ □ □ □ □
Alter 2 □ □ □ □ □ □ □
Alter 3 □ □ □ □ □ □ □
Alter 4 □ □ □ □ □ □ □
Alter 5 □ □ □ □ □ □ □
Alter 6 □ □ □ □ □ □ □
Alter 7 □ □ □ □ □ □ □
Alter 8 □ □ □ □ □ □ □
Alter 9 □ □ □ □ □ □ □
Alter 10 □ □ □ □ □ □ □
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MEASURE of Network Composition
 Independent variable II: Network_Range
Basic 
Scientist 
(NHS, Uni)
Clinical 
Scientist 
(NHS, Uni)
Medical Doctor 
(not involved 
in research)
Patient or 
Patient 
Associations
Industry / 
Private 
Sector
Public 
Administ
Others 
(specify)
Alter 1 □ □ □ □ □ □ □
Alter 2 □ □ □ □ □ □ □
Alter 3 □ □ □ □ □ □ □
Alter 4 □ □ □ □ □ □ □
Alter 5 □ □ □ □ □ □ □
Alter 6 □ □ □ □ □ □ □
Alter 7 □ □ □ □ □ □ □
Alter 8 □ □ □ □ □ □ □
Alter 9 □ □ □ □ □ □ □
Alter 10 □ □ □ □ □ □ □
We grouped the alters in these 4 categories.
This measure is build from another question in the survey, asking for the following 
information about the contacts cited by the respondent:
“Indicate the sector or professional field of the persons you have cited as being a particularly 
important source of information or advice for your research activities” (drop-down menu)
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MEASURE of Network Composition
 Independent variable II: Network_Range
We constructed our variable Network_Range as the count of sector / 
professional categories of the alters that compose an individual’s network. 
Network_range takes values from 0 (no external contacts) to 4 (external 
contacts belonging to the four categories of sectors or professional activity).
About 70% of our respondents report having external contacts who belong to 1 
or 2 distinct categories of sectors or professional activity. 
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MEASURE of Cognitive Skills
 Independent variable III: Breadth of cognitive skills
The survey included the following question: 
“Have you received, through your career, specific training in one or more of the 
following activities?” (tick where appropriate)
Design of clinical trials □
Design of clinical guidelines □
State-of-the-technology in your field of research □
Clinical pharmacology □
Biostatistics □
Molecular biology □
Experimental methods □
Experimentation with animals □
Studies with control groups □
Cognitive Breadth: 
Measured as the 
count of areas of 
‘specific training’
Mean: 2.71
Median: 3.00
Mode: 2.00
Min:  0.00
Max: 9.00
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MEASURE of Perceived Impact on Beneficiaries 
 Independent variable IV: Perceived impact on beneficiaries
The survey included the following question:
“Please, indicate the extent to which you consider that the following collectives benefit 
more directly from the results obtained from your research activities” (responses 
according to a 7 point Likert Scale – from ‘not at all’ to ‘very much’)
Collectives 1 2 3 4 5 6 7
Patients □ □ □ □ □ □ □
Clinical Practitioners □ □ □ □ □ □ □
Patients’ relatives □ □ □ □ □ □ □
– We averaged the responses to the three items to create a composite indicator of 
the perceived clinical impact of the research activities (Cronbach’s Alpha = 0, 78)
Perceived impact on beneficiaries:
Mean: 4.44  /   Median: 4.50  /   Mode: 5.00  /   Min:  1.00  /   Max: 7.00
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Control Variables and Econometric Methods
 Control variables
Individual level:
• Age & Gender
• PhD degree
• Size of external network
• Patent applications over period 1990-2010
Organizational and Institutional
• Size of the research team
• Institutional affiliation: University, Hospital, PROs and Others
• Type of CIBER
 Econometric Method 
Ordered Probit / Logit, Fractional Logit and OLS regression methods
• Dependent variable that ranges between 0 and 3 (Ordered Logit / Probit)
• Re-scale the variable to obtain a measure between 0 and 1: Pi = (Yi – Ymin) / (Ymax – Ymin) (F.Log.)
Consider two samples
• Complete sample, controlling for cases with zero or one external contact (1111 obs.)
• Restricted sample: considering only those cases who report having 2 or more external 
contacts (820 obs.)
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RESULTS (Ordered Probit) 
* p < 0.1, ** p < 0.05, *** p < 0.01 /    * N. Observations = 820 (scientists who reported at least 2 external contacts)
Total Sample (1111 obs.) Restricted Sample (820 obs.)*
(1a) (2a) (3a) (4a) (1b) (2b) (3b) (4b)
Predictor Variables
Ego Net. Brokerage
Ego Net. Brokerage2
Network Range
Network Range2
Cognitive Breadth
Perc.Impact Benef.
Control Variables
Age
PhD
Large Ego-Network
Past Patent Applicat.
Gender (female=1)
Group Size
University
Hospital
PROs
CIBER (8 dummies)
Ext_net.< 2 (dummy)
Ps-R2 (Cragg-Uhler)
Dependent variable: Degree of engagement in medical innovation activities (outcome values: 0 - 3)
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RESULTS (Ordered Probit) 
* p < 0.1, ** p < 0.05, *** p < 0.01 /    * N. Observations = 820 (scientists who reported at least 2 external contacts)
Total Sample (1111 obs.) Restricted Sample (820 obs.)*
(1a) (2a) (3a) (4a) (1b) (2b) (3b) (4b)
Predictor Variables
Ego Net. Brokerage
Ego Net. Brokerage2
Network Range
Network Range2
Cognitive Breadth
Perc.Impact Benef.
Control Variables
Age 0.021*** 0.022***
PhD 0.092 -0.001
Large Ego-Network 0.195** 0.194**
Past Patent Applicat. 0.037*** 0.033*
Gender (female=1) -0.361*** -0.374***
Group Size 0.004 0.005
University 0.003 -0.098
Hospital 0.805*** 0.766***
PROs 0.133 0.112
CIBER (8 dummies) Included Included
Ext_net.< 2 (dummy) -0.143 ---
Ps-R2 (Cragg-Uhler) 0.24 0.22
Dependent variable: Degree of engagement in medical innovation activities (outcome values: 0 - 3)
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RESULTS (Ordered Probit) 
* p < 0.1, ** p < 0.05, *** p < 0.01 /    * N. Observations = 820 (scientists who reported at least 2 external contacts)
Total Sample (1111 obs.) Restricted Sample (820 obs.)*
(1a) (2a) (3a) (4a) (1b) (2b) (3b) (4b)
Predictor Variables
Ego Net. Brokerage 1.103** 1.144**
Ego Net. Brokerage2 -0.917** -0.937**
Network Range --- ---
Network Range2 --- ---
Cognitive Breadth 0078*** 0.091***
Perc.Impact Benef. 0.188*** 0.207***
Control Variables
Age 0.021*** 0.021*** 0.022*** 0.021***
PhD 0.092 0.092 -0.001 -0.013
Large Ego-Network 0.195** 0.025 0.194** 0.013
Past Patent Applicat. 0.037*** 0.044*** 0.033* 0.036**
Gender (female=1) -0.361*** -0.376*** -0.374*** -0.394***
Group Size 0.004 0.006 0.005 0.007
University 0.003 0.053 -0.098 -0.042
Hospital 0.805*** 0.736*** 0.766*** 0.701***
PROs 0.133 0.157 0.112 0.153
CIBER (8 dummies) Included Included Included Included
Ext_net.< 2 (dummy) -0.143 0.081 --- ---
Ps-R2 (Cragg-Uhler) 0.24 0.30 0.22 0.29
Dependent variable: Degree of engagement in medical innovation activities (outcome values: 0 - 3)
H1
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RESULTS: NETWORK BROKERAGE AND MEDICAL INNOVATION
 Curvilinear relationship between network brokerage and engagement in medical 
innovation
The highest participation in medical innovation happens at intermediate levels of 
network brokerage
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RESULTS (Ordered Probit) 
* p < 0.1, ** p < 0.05, *** p < 0.01 /    * N. Observations = 820 (scientists who reported at least 2 external contacts)
Total Sample (1111 obs.) Restricted Sample (820 obs.)*
(1a) (2a) (3a) (4a) (1b) (2b) (3b) (4b)
Predictor Variables
Ego Net. Brokerage 1.103** --- 1.144** ---
Ego Net. Brokerage2 -0.917** --- -0.937** ---
Network Range --- 0.164** --- 0.133
Network Range2 --- -0.027 --- -0.010
Cognitive Breadth 0078*** 0.075*** 0.091*** 0.087***
Perc.Impact Benef. 0.188*** 0.181*** 0.207*** 0.195***
Control Variables
Age 0.021*** 0.021*** 0.021*** 0.022*** 0.021*** 0.021***
PhD 0.092 0.092 0.084 -0.001 -0.013 -0.019
Large Ego-Network 0.195** 0.025 0.041 0.194** 0.013 0.040
Past Patent Applicat. 0.037*** 0.044*** 0.044*** 0.033* 0.036** 0.036*
Gender (female=1) -0.361*** -0.376*** -0.386*** -0.374*** -0.394*** -0.404***
Group Size 0.004 0.006 0.006 0.005 0.007 0.006
University 0.003 0.053 0.067 -0.098 -0.042 -0.028
Hospital 0.805*** 0.736*** 0.738*** 0.766*** 0.701*** 0.702***
PROs 0.133 0.157 0.176 0.112 0.153 0.166
CIBER (8 dummies) Included Included Included Included Included Included
Ext_net.< 2 (dummy) -0.143 0.081 0.084 --- --- ---
Ps-R2 (Cragg-Uhler) 0.24 0.30 0.30 0.22 0.29 0.29
Dependent variable: Degree of engagement in medical innovation activities (outcome values: 0 - 3)
H2
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RESULTS (Ordered Probit) 
* p < 0.1, ** p < 0.05, *** p < 0.01 /    * N. Observations = 820 (scientists who reported at least 2 external contacts)
Total Sample (1111 obs.) Restricted Sample (820 obs.)*
(1a) (2a) (3a) (4a) (1b) (2b) (3b) (4b)
Predictor Variables
Ego Net. Brokerage 1.103** --- 1.144** ---
Ego Net. Brokerage2 -0.917** --- -0.937** ---
Network Range --- 0.164** --- 0.133
Network Range2 --- -0.027 --- -0.010
Cognitive Breadth 0078*** 0.075*** 0.091*** 0.087***
Perc.Impact Benef. 0.188*** 0.181*** 0.207*** 0.195***
Control Variables
Age 0.021*** 0.021*** 0.021*** 0.022*** 0.021*** 0.021***
PhD 0.092 0.092 0.084 -0.001 -0.013 -0.019
Large Ego-Network 0.195** 0.025 0.041 0.194** 0.013 0.040
Past Patent Applicat. 0.037*** 0.044*** 0.044*** 0.033* 0.036** 0.036*
Gender (female=1) -0.361*** -0.376*** -0.386*** -0.374*** -0.394*** -0.404***
Group Size 0.004 0.006 0.006 0.005 0.007 0.006
University 0.003 0.053 0.067 -0.098 -0.042 -0.028
Hospital 0.805*** 0.736*** 0.738*** 0.766*** 0.701*** 0.702***
PROs 0.133 0.157 0.176 0.112 0.153 0.166
CIBER (8 dummies) Included Included Included Included Included Included
Ext_net.< 2 (dummy) -0.143 0.081 0.084 --- --- ---
Ps-R2 (Cragg-Uhler) 0.24 0.30 0.30 0.22 0.29 0.29
Dependent variable: Degree of engagement in medical innovation activities (outcome values: 0 - 3)
H3
H4
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RESULTS (Ordered Probit) 
* p < 0.1, ** p < 0.05, *** p < 0.01 /    * N. Observations = 820 (scientists who reported at least 2 external contacts)
Total Sample (1111 obs.) Restricted Sample (820 obs.)*
(1a) (2a) (3a) (4a) (1b) (2b) (3b) (4b)
Predictor Variables
Ego Net. Brokerage 1.103** --- 0.979** 1.144** --- 1.048**
Ego Net. Brokerage2 -0.917** --- -0.386* -0.937** --- -0.875**
Network Range --- 0.164** 0.125** --- 0.133 0.097
Network Range2 --- -0.027 --- --- -0.010 ---
Cognitive Breadth 0078*** 0.075*** 0.075*** 0.091*** 0.087*** 0.088***
Perc.Impact Benef. 0.188*** 0.181*** 0.183*** 0.207*** 0.195*** 0.201***
Control Variables
Age 0.021*** 0.021*** 0.021*** 0.021*** 0.022*** 0.021*** 0.021*** 0.021***
PhD 0.092 0.092 0.084 0.086 -0.001 -0.013 -0.019 -0.018
Large Ego-Network 0.195** 0.025 0.041 -0.035 0.194** 0.013 0.040 -0.032
Past Patent Applicat. 0.037*** 0.044*** 0.044*** 0.044*** 0.033* 0.036** 0.036* 0.036**
Gender (female=1) -0.361*** -0.376*** -0.386*** -0.387*** -0.374*** -0.394*** -0.404*** -0.405***
Group Size 0.004 0.006 0.006 0.006 0.005 0.007 0.006 0.007
University 0.003 0.053 0.067 0.060 -0.098 -0.042 -0.028 -0.037
Hospital 0.805*** 0.736*** 0.738*** 0.733*** 0.766*** 0.701*** 0.702*** 0.697***
PROs 0.133 0.157 0.176 0.167 0.112 0.153 0.166 0.159
CIBER (8 dummies) Included Included Included Included Included Included Included Included
Ext_net.< 2 (dummy) -0.143 0.081 0.084 0.184 --- --- --- ---
Ps-R2 (Cragg-Uhler) 0.24 0.30 0.30 0.30 0.22 0.29 0.29 0.29
Dependent variable: Degree of engagement in medical innovation activities (outcome values: 0 - 3)
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PRELIMINARY CONCLUSIONS
 What type of personal networks are most conducive to innovation?
 Our results suggest that:
– A. The structure of scientists’ collaboration network does influence innovation
... but it is important to keep an appropriate balance between sparse and dense
network structures
• Scientists devoting efforts to cultivate a sparse network are more strongly engaged in
medical innovation
• However, maintaining sparse networks may undermine trust or involve coordination
difficulties
 Most effective network structures combine elements associated to both dense and
sparse networks
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PRELIMINARY CONCLUSIONS
– B. We find partial evidence of a positive impact of Network range on innovation
• Networks composed of heterogeneous actors seem to be conducive to innovation among
scientists
 However, contrary to ego-network brokerage, the potential benefits of having a divers network
does not show decreasing returns.
 These results do not hold for the restricted sample: low variability of network range (85% of obs.
have a range score of 1or 2).
– C. Network structures should be analyzed in conjunction with Individual attributes:
 Cognitive breadth: the higher the diversity of (basic & clinical) skills, the higher the
probability of scientists to engage in medical innovation
 More Inter-disciplinary univ. degree programs - bridging basic and clinical research requires sets
of skills that are not typically offered by traditional curricula
 Perceived impact on beneficiaries: scientists who are particularly aware of the positive
impact they exert on patients and clinical practitioners are more prone to engage in
multiple forms of medical innovation
 Our results support Soc. Psych. Lit. suggesting that when individuals perceive that their actions
have an impact on beneficiaries, they are particularly motivated to make a positive difference in
the wellbeing of these beneficiaries (e.g. developing new med. treatments)
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VARIABLES (II)
Independent variable I: Ego-network brokerage
“Write down the names of those persons (up to ten) from outside your research 
group that are particularly important for the advancement of your research activities”
Ego-network
brokerage 
Number of alter-alter ties
total number of possible
alter-alter ties
=
Independent variable II: Breadth of cognitive skills
“Have you received, though your career, training on one or more of the following activities?”
Battery of 8 skills. E.g.: “development of clinical trials”, “biostatistics”, “molecular biology” , 
“experimental methods”
Min = 0 (lowest brokerage) 
Max = 1 (highest brokerage)
Independent variable III: Perceived impact on beneficiaries
“Please, indicate the extent to which the following collectivities benefit more directly from 
the results obtained from your research activities” (Likert scale, 1 -7)
a) Research community,
b) Patients; 
c) Clinical practitioners
d) Vulnerable social groups
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RESEARCH CONTEXT AND METHODS (II)
Response rates by CIBER:
CIBER Population 
surveyed
No Complete 
Returned 
Questionnaires
Response 
rates (%)
BBN-Bioeng.,Biomaterials & Nanomed. 872 238 27.3
DEM-Diabetes & Metabolic A. Diseases 331 96 29.0
EHD-Hepatic Diseases 459 154 33.6
ER-Rare Diseases 517 177 34.2
ES-Respiratory Diseases 439 159 36.2
ESP-Epidemiology & Public Health 610 107 17.5
NED-Neurodegenerative Diseases 750 186 24.8
OBN-Obesity & Nutrition 303 71 23.4
SAM-Mental Health 477 121 25.4
Total 4758 1309 27.5
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MEASURE of Network Composition
 Independent variable II: Network_Range
Proportion of individuals who report having at least one contact corresponding 
to each of the four sector / professional categories
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E.g.: About 60% of our respondents report that at least one of their (external) 
informants were Basic Scientists. 
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…. Should “optimal” network configurations lay somewhere in-between?     
Personal networks where actors enjoy the advantages of both types of structures
BACKGROUND
Brokerage opportunities Cohesion and trust
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MEASURE of Network Structure
 Independent variable I: Ego-network brokerage
The survey included the following question:
“Write down the names of those persons (up to ten) from outside your research group who have 
been a particularly important source of information or advice for the advancement of your 
research activities in 2012”
A subsequent question was then activated with the following matrix (size depending on the 
number of alters reported) asking for the following information: 
“Indicate if, according to your knowledge, the persons you have cited exchange information  or 
advice with each other, in connection with their professional activities” (tick as many as appropriate)
Alter 1 Alter 2 Alter 3 Alter 4 Alter 5 Alter 6 Alter 7 Alter 8 Alter 9
Alter 2 □
Alter 3 □ □
Alter 4 □ □ □
Alter 5 □ □ □ □
Alter 6 □ □ □ □ □
Alter 7 □ □ □ □ □ □
Alter 8 □ □ □ □ □ □ □
Alter 9 □ □ □ □ □ □ □ □
Alter 10 □ □ □ □ □ □ □ □ □
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MEASURE of Network Structure
 Independent variable I: Ego-network brokerage
Network structure measures are computed for two samples
Whole sample: N. Obs. 1309
• Includes all obs., including those cases 
reporting zero or 1 external contacts
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Brokerage (restricted sample)
Restricted sample: N. Obs. 949
• Includes only those cases reporting 
2 or more  external contacts
142 cases142 + 343 cases
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PRELIMINARY CONCLUSIONS
– Avenues for further research:
 Variety of indicators for medical innovation: (i) drug development, (ii) clinical
guidelines, (iii) invention and commercialization: and (iv) diagnostics/prevention:
 Results by type of medical innovation
 Distinct explanatory factors from different types of brokerage
 Moderating factors:
 Interplay between Structure and Composition
 Network configuration – Individual Attributes
 Scientific performance:
 to explore whether scientific excellence is a predictor of engagement in med. Innov.
 to examine whether scientific performance could contribute to enact personal
networks
 Differences in network configurations for innovation and scientific discoveries
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PRELIMINARY CONCLUSIONS
– Individual attributes should be explicitly considered as they critically contribute to
knowledge creation (in addition to network features):
 Cognitive breadth: the higher the diversity of (basic & clinical) skills, the higher the
probability of scientists to engage in medical innovation
 More Inter-disciplinary univ. degree programs - bridging basic and clinical research requires
sets of skills that are not typically offered by traditional curricula
 Perceived impact on beneficiaries: scientists who are particularly aware of the
positive impact they exert on patients and clinical practitioners exhibit a stronger
engagement in multiple forms of medical innovation
 Our results support Soc. Psych. Lit. suggesting that when individuals perceive that their
actions have an impact on beneficiaries, they become particularly motivated to make a positive
difference in the wellbeing of these beneficiaries (developing new med. treatments)
 Implementation of mechanisms to increase scientists’ awareness of the practical impact on
patients and clinical practitioners, to foster their participation in medical innovation activities:
particularly among basic scientists
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RESULTS (Ordered Probit) 
* p < 0.1, ** p < 0.05, *** p < 0.01 /    * N. Observations = 820 (scientists who reported at least 2 external contacts)
Total Sample (1111 obs.) Restricted Sample (820 obs.)*
(1a) (2a) (3a) (4a) (1b) (2b) (3b) (4b)
Predictor Variables
Ego Net. Brokerage 1.103** --- 0.979** 1.144** --- 1.048**
Ego Net. Brokerage2 -0.917** --- -0.386* -0.937** --- -0.875**
Network Range --- 0.164** 0.125** --- 0.133 0.097
Network Range2 --- -0.027 --- --- -0.010 ---
Cognitive Breadth 0078*** 0.075*** 0.075*** 0.091*** 0.087*** 0.088***
Perc.Impact Benef. 0.188*** 0.181*** 0.183*** 0.207*** 0.195*** 0.201***
Control Variables
Age 0.021*** 0.021*** 0.021*** 0.021*** 0.022*** 0.021*** 0.021*** 0.021***
PhD 0.092 0.092 0.084 0.086 -0.001 -0.013 -0.019 -0.018
Large Ego-Network 0.195** 0.025 0.041 -0.035 0.194** 0.013 0.040 -0.032
Past Patent Applicat. 0.037*** 0.044*** 0.044*** 0.044*** 0.033* 0.036** 0.036* 0.036**
Gender (female=1) -0.361*** -0.376*** -0.386*** -0.387*** -0.374*** -0.394*** -0.404*** -0.405***
Group Size 0.004 0.006 0.006 0.006 0.005 0.007 0.006 0.007
University 0.003 0.053 0.067 0.060 -0.098 -0.042 -0.028 -0.037
Hospital 0.805*** 0.736*** 0.738*** 0.733*** 0.766*** 0.701*** 0.702*** 0.697***
PROs 0.133 0.157 0.176 0.167 0.112 0.153 0.166 0.159
CIBER (8 dummies) Included Included Included Included Included Included Included Included
Ext_net.< 2 (dummy) -0.143 0.081 0.084 0.184 --- --- --- ---
Ps-R2 (Cragg-Uhler) 0.24 0.30 0.30 0.30 0.22 0.29 0.29 0.29
Dependent variable: Degree of engagement in medical innovation activities (outcome values: 0 - 3)
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VARIABLES
 Proportion of scientists who participate in the different types of medical
innovation, by type of Institution (%)
Invention & 
Commercializ.
Drug 
Development
Clinical 
Guidelines
Diagnostics 
& Prevention
Total 
obs.
Universisty 19,2 7,5 11,7 8,8 386
Hospitals 12,0 41,4 47,8 12,5 409
Public Research 
Centres
15,5 8,8 9,4 10,3 341
Private Research 
Centres & Others
15,2 8,8 12,0 7,2 125
Total 15,5 19,0 22,8 10,2 1261
